Australia's Neurizon Therapeutics jumps after US FDA clears ALS product for trial use

Neurizon Therapeutics

11/12/2025 02:13

** Shares of Australia's Neurizon Therapeutics NUZ.AX jump as much as 8.7% to A$0.125, their highest since November 20

** Neurodegenerative disease-focused biotech co says the U.S. Food and Drug Administration has cleared the use of its "NUZ001 regimen" in the HEALEY ALS platform trial

** NUZ-001 is a potential treatment option for people living with amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disorder

** YTD, shares down 32.4%

 (Reporting by Shruti Agarwal in Bengaluru)

 ((Shruti.Agarwal@thomsonreuters.com))